Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Leukemia 40Lymphoma 39Melanoma 27Leukemia, Lymphocytic, Chronic, B-Cell 27Lymphoma, Non-Hodgkin 24Lymphoma, Follicular 24Precursor Cell Lymphoblastic Leukemia-Lymphoma 23Breast Neoplasms 21Lymphoma, Large B-Cell, Diffuse 20Lymphoma, Mantle-Cell 19Myelodysplastic Syndromes 17Neuroblastoma 16Lymphoma, Large-Cell, Immunoblastic 16Hodgkin Disease 16Multiple Myeloma 15Leukemia, Myeloid, Chronic-Phase 15Leukemia, Myeloid, Acute 15Burkitt Lymphoma 15Lymphoma, B-Cell, Marginal Zone 14Leukemia, Myelogenous, Chronic, BCR-ABL Positive 14Prostatic Neoplasms 13Neoplasm Metastasis 13Carcinoma, Non-Small-Cell Lung 12Lung Neoplasms 11Neoplasms, Plasma Cell 10Leukemia, Myeloid, Accelerated Phase 10Glioblastoma 10Congenital Abnormalities 10Carcinoma, Ovarian Epithelial 9Ovarian Neoplasms 8

Interventions

Docetaxel 3Prednisone 2sargramostim 1epothilone B 1cabazitaxel 1Sunitinib 1PE regimen 1Interleukin-2 1Injections 1Everolimus 1Etoposide 1Cyclophosphamide 1Cisplatin 1Carboplatin 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Hormone Refractory Prostate Cancer × sargramostim × Clear all
NCT00313482 2012-05-11

PII Trial of Docetaxel/Prednisone w/Sargramostim for HRPC

Veeda Oncology

Phase 2 Terminated
35 enrolled
Genitourinary

Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡